Top

Published in:

Open Access 01-12-2018 | Research article

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Authors: Licia Grazzi, Cristina Tassorelli, Marina de Tommaso, Giulia Pierangeli, Paolo Martelletti, Innocenzo Rainero, Pierangelo Geppetti, Anna Ambrosini, Paola Sarchielli, Eric Liebler, Piero Barbanti, on Behalf of the PRESTO Study Group

Published in: The Journal of Headache and Pain | Issue 1/2018

Abstract

Background

The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication.

Methods

Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified by pain intensity at treatment initiation.

Results

A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123) reported a ≥ 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013) and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%; sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%; sham, 30.1%; P = 0.037).

Conclusions

This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic medications and their associated adverse events.

Trial registration

ClinicalTrials.gov identifier: NCT02686034.

Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G (2015) Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain 16:61. https://doi.org/10.1186/s10194-015-0542-4 CrossRefPubMedPubMedCentral

Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA (2014) Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia 34(12):986–993. https://doi.org/10.1177/0333102414524494 CrossRefPubMed

Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H (2015) Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain 16:101. https://doi.org/10.1186/s10194-015-0582-9 CrossRefPubMedPubMedCentral

Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, Dorlas S, Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P, Group PS (2018) Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology 91(4):e364–e373. https://doi.org/10.1212/WNL.0000000000005857 CrossRefPubMedPubMedCentral

Buse DC, Serrano D, Reed ML, Kori SH, Cunanan CM, Adams AM, Lipton RB (2015) Adding additional acute medications to a triptan regimen for migraine and observed changes in headache-related disability: results from the American migraine prevalence and prevention (AMPP) study. Headache 55(6):825–839. https://doi.org/10.1111/head.12556 CrossRefPubMed

Lipton RB, Buse DC, Serrano D, Holland S, Reed ML (2013) Examination of unmet treatment needs among persons with episodic migraine: results of the American migraine prevalence and prevention (AMPP) study. Headache 53(8):1300–1311. https://doi.org/10.1111/head.12154 CrossRefPubMed

Puledda F, Goadsby PJ (2017) An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache 57(4):685–691. https://doi.org/10.1111/head.13069 CrossRefPubMed

Puledda F, Messina R, Goadsby PJ An update on migraine: current understanding and future directions. J Neurol 264(9):2031–2039. https://doi.org/10.1007/s00415-017-8434-y

Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32(1):6–38. https://doi.org/10.1177/0333102411417901 CrossRefPubMed

10.

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38(1):1–211.

11.

Martelletti P, Barbanti P, Grazzi L, Pierangeli G, Rainero I, Geppetti P, Ambrosini A, Sarchielli P, Tassorelli C, Liebler E, de Tommaso M (2018) Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial [abstract MTIS2018-060]. Cephalalgia 28(1S):43. https://doi.org/10.1177/0333102418789865 CrossRef

12.

Cady R, Elkind A, Goldstein J, Keywood C (2004) Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 20(9):1465–1472. https://doi.org/10.1185/030079904x2745 CrossRefPubMed

13.

Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R (2000) Prevention of migraine during prodrome with naratriptan. Cephalalgia 20(2):122–126. https://doi.org/10.1046/j.1468-2982.2000.00030.x CrossRefPubMed

14.

Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J (2008) Early vs. non-early intervention in acute migraine-'Act when mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28(4):383–391. https://doi.org/10.1111/j.1468-2982.2008.01546.x CrossRefPubMed

15.

Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L, Wright P, Greenberg SJ (2007) Early intervention with almotriptan: results of the AEGIS trial (AXERT early migraine intervention study). Headache 47(2):189–198. https://doi.org/10.1111/j.1526-4610.2006.00686.x CrossRefPubMed

16.

Freitag FG, Finlayson G, Rapoport AM, Elkind AH, Diamond ML, Unger JR, Fisher AC, Armstrong RB, Hulihan JF, Greenberg SJ (2007) Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg time versus intensity migraine study (AIMS). Headache 47(4):519–530. https://doi.org/10.1111/j.1526-4610.2007.00756.x CrossRefPubMed

17.

Foley KA, Cady R, Martin V, Adelman J, Diamond M, Bell CF, Dayno JM, Hu XH (2005) Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 45(5):538–545. https://doi.org/10.1111/j.1526-4610.2005.05107.x CrossRefPubMed

18.

Becker WJ, Findlay T, Moga C, Scott NA, Harstall C, Taenzer P (2015) Guideline for primary care management of headache in adults. Can Fam Physician 61(8):670–679PubMedPubMedCentral

19.

Rapoport AM (2008) Acute and prophylactic treatments for migraine: present and future. Neurol Sci 29(Suppl 1):S110–S122. https://doi.org/10.1007/s10072-008-0901-x CrossRefPubMed

20.

Ozturk V (2013) Acute treatment of migraine. Noro Psikiyatr Ars 50(Suppl 1):S26–s29. https://doi.org/10.4274/Npa.y7299 CrossRefPubMedPubMedCentral

21.

Pilgrim AJ (1991) Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 31(5):295–299. https://doi.org/10.1159/000116757 CrossRefPubMed

22.

Akerman S, Simon B, Romero-Reyes M (2017) Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache. Neurobiol Dis 102:96–104. https://doi.org/10.1016/j.nbd.2017.03.004 CrossRefPubMed

23.

Oshinsky ML, Murphy AL, Hekierski H, Jr., Cooper M, Simon BJ (2014) Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain 155 (5):1037–1042. doi:https://doi.org/10.1016/j.pain.2014.02.009

24.

Chen SP, Ay I, de Morais AL, Qin T, Zheng Y, Sadeghian H, Oka F, Simon B, Eikermann-Haerter K, Ayata C (2016) Vagus nerve stimulation inhibits cortical spreading depression. Pain 157(4):797–805. https://doi.org/10.1097/j.pain.0000000000000437 CrossRefPubMedPubMedCentral

25.

Hawkins JL, Cornelison LE, Blankenship BA, Durham PL (2017) Vagus nerve stimulation inhibits trigeminal nociception in a rodent model of episodic migraine. Pain Rep 2(6):e628. https://doi.org/10.1097/pr9.0000000000000628 CrossRefPubMedPubMedCentral

26.

Giamberardino MA, Affaitati G, Martelletti P, Tana C, Negro A, Lapenna D, Curto M, Schiavone C, Stellin L, Cipollone F, Costantini R (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain 17:28. https://doi.org/10.1186/s10194-016-0619-8 CrossRefPubMed

27.

Yuan H, Silberstein SD (2016) Vagus nerve and vagus nerve stimulation, a comprehensive review: part I. Headache 56(1):71–78. https://doi.org/10.1111/head.12647 CrossRefPubMed

28.

Vecchio E, Bassez I, Ricci K, Tassorelli C, Liebler E, de Tommaso M (2018) Effect of non-invasive vagus nerve stimulation on resting-state electroencephalography and laser-evoked potentials in migraine patients: mechanistic insights. Front Hum Neurosci 12:366

29.

de Tommaso M (2012) Prevalence, clinical features and potential therapies for fibromyalgia in primary headaches. Expert Rev Neurother 12(3):287–295; quiz 296. https://doi.org/10.1586/ern.11.190 CrossRefPubMed

30.

Lange G, Janal MN, Maniker A, Fitzgibbons J, Fobler M, Cook D, Natelson BH (2011) Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. Pain Med 12(9):1406–1413. https://doi.org/10.1111/j.1526-4637.2011.01203.x CrossRefPubMedPubMedCentral

31.

Curran-Everett D, Milgrom H (2013) Post-hoc data analysis: benefits and limitations. Curr Opin Allergy Clin Immunol 13(3):223–224. https://doi.org/10.1097/ACI.0b013e3283609831 CrossRefPubMed

32.

Elliott HL (1996) Post hoc analysis: use and dangers in perspective. J Hypertens Suppl 14 (2):S21-24; discussion S24-25

33.

Srinivas TR, Ho B, Kang J, Kaplan B (2015) Post hoc analyses: after the facts. Transplantation 99(1):17–20. https://doi.org/10.1097/tp.0000000000000581 CrossRefPubMed

34.

Moeller M, Schroeder CF, May A (2018) Comparison of active and “sham” non-invasive vagal nerve stimulation on lacrimation in healthy volunteers. Headache 58(S2):195. https://doi.org/10.1111/head.13306 CrossRef

35.

Martelletti P (2017) Acute treatment of migraine: quo vadis? Expert Opin Pharmacother 18(11):1035–1037. https://doi.org/10.1080/14656566.2017.1329821 CrossRefPubMed

36.

Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ (2017) Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia 37(10):965–978. https://doi.org/10.1177/0333102416660552 CrossRefPubMed

37.

Sabato D, Lionetto L, Martelletti P (2015) The therapeutic potential of novel anti-migraine acute therapies. Expert Opin Investig Drugs 24(2):141–144. https://doi.org/10.1517/13543784.2015.983223 CrossRefPubMed

38.

Goadsby PJ (2008) The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia 28(Suppl 2):36–41. https://doi.org/10.1111/j.1468-2982.2008.01689.x CrossRefPubMed

Title: Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial
Authors: Licia Grazzi
Cristina Tassorelli
Marina de Tommaso
Giulia Pierangeli
Paolo Martelletti
Innocenzo Rainero
Pierangelo Geppetti
Anna Ambrosini
Paola Sarchielli
Eric Liebler
Piero Barbanti
on Behalf of the PRESTO Study Group
Publication date: 01-12-2018
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-018-0928-1

At a glance: The STEP trials

Springer Medicine

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Abstract

Background

Methods

Results

Conclusions

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Evaluation of gray matter perfusion in episodic migraine using voxel-wise comparison of 3D pseudo-continuous arterial spin labeling

Aggression and its association with suicidality in migraine patients: a case-control study

The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

Headache attributed to aeroplane travel: the first multicentric survey in a paediatric population affected by primary headaches